Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in radioactive iodine-refractory differentiated thyroid carcinoma
ChiCTR-OIN-17012199Phase 2Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jul 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in well-differentiated thyroid cancer (WDTC), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: Progression-free survival. Started Jul 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR-OIN-17012199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17012199.